Previous close | 1.1500 |
Open | 0.5500 |
Bid | 1.1500 |
Ask | 1.8500 |
Strike | 5.00 |
Expiry date | 2024-05-17 |
Day's range | 0.5500 - 1.1500 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Lyra Therapeutics ( NASDAQ:LYRA ) First Quarter 2024 Results Key Financial Results Net loss: US$22.5m (loss widened by...
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. “With results